Crinetics Pharmaceuticals (CRNX) Competitors $31.37 +0.42 (+1.36%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$31.27 -0.10 (-0.32%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, BBIO, BPMC, and ELANShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Dr. Reddy's Laboratories Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines BridgeBio Pharma Blueprint Medicines Elanco Animal Health Dr. Reddy's Laboratories (NYSE:RDY) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Does the MarketBeat Community believe in RDY or CRNX? Dr. Reddy's Laboratories received 163 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.43% of users gave Crinetics Pharmaceuticals an outperform vote while only 59.41% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32259.41% Underperform Votes22040.59% Crinetics PharmaceuticalsOutperform Votes15969.43% Underperform Votes7030.57% Is RDY or CRNX more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Crinetics Pharmaceuticals N/A -36.12%-31.89% Which has higher earnings and valuation, RDY or CRNX? Dr. Reddy's Laboratories has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$325.54B0.04$668M$0.6621.94Crinetics Pharmaceuticals$760K3,864.66-$214.53M-$3.82-8.21 Does the media refer more to RDY or CRNX? In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Crinetics Pharmaceuticals and 11 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.61 beat Crinetics Pharmaceuticals' score of 0.99 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Crinetics Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of RDY or CRNX? 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, RDY or CRNX? Dr. Reddy's Laboratories has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Do analysts prefer RDY or CRNX? Dr. Reddy's Laboratories presently has a consensus price target of $17.00, suggesting a potential upside of 17.40%. Crinetics Pharmaceuticals has a consensus price target of $73.00, suggesting a potential upside of 132.71%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 SummaryDr. Reddy's Laboratories beats Crinetics Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.94B$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-8.419.1426.8320.05Price / Sales3,864.66255.59394.87116.44Price / CashN/A65.8538.2534.62Price / Book3.896.546.874.61Net Income-$214.53M$143.51M$3.22B$248.19M7 Day Performance0.26%5.60%6.82%2.97%1 Month Performance4.05%10.06%13.72%16.58%1 Year Performance-36.63%-0.86%18.31%8.16% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.7086 of 5 stars$31.37+1.4%$73.00+132.7%-38.0%$2.94B$760,000.00-8.41210RDYDr. Reddy's Laboratories2.3617 of 5 stars$13.93+3.9%$17.00+22.1%+5.3%$11.62B$311.31B22.1724,800Positive NewsGap UpVTRSViatris2.1288 of 5 stars$8.96+2.2%$10.50+17.2%-19.8%$10.63B$14.33B-12.1137,000Trending NewsGap UpMRNAModerna4.5272 of 5 stars$25.70+6.0%$53.95+109.9%-80.2%$9.94B$3.14B-2.773,900Trending NewsQGENQiagen4.0535 of 5 stars$42.92+2.5%$48.42+12.8%-3.4%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.5483 of 5 stars$154.43+2.1%$216.07+39.9%+33.5%$9.42B$368.70M-21.75640Positive NewsROIVRoivant Sciences2.0132 of 5 stars$10.99+3.3%$17.50+59.2%-2.9%$7.84B$122.59M-73.26860Positive NewsRVMDRevolution Medicines4.4159 of 5 stars$41.88+3.6%$67.17+60.4%+1.1%$7.80B$742,000.00-11.67250Positive NewsBBIOBridgeBio Pharma4.6499 of 5 stars$35.68+4.4%$57.09+60.0%+14.2%$6.77B$127.42M-12.52400Positive NewsInsider TradeBPMCBlueprint Medicines1.8307 of 5 stars$100.31+3.2%$126.56+26.2%-1.2%$6.48B$562.12M-92.88640Positive NewsELANElanco Animal Health3.2726 of 5 stars$12.82+7.2%$15.00+17.0%-23.1%$6.36B$4.43B32.049,800Analyst ForecastGap Up Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Viatris Competitors Moderna Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
